Vazopro of the capsule

General characteristics. Structure:

Active ingredient: meldoniya;

1 capsule contains a metonata (meldoniya) in terms of 100% substance of 250 mg or 500 mg;

excipients: potato starch, silicon dioxide colloid anhydrous, calcium stearate;

structure of a cover of the capsule: gelatin, titanium dioxide (Е 171), azoruby, кармоизин (Е 122).

Pharmacological properties:

Pharmacodynamics. Vazopro – a structural analog of a γ-butyrobetaine – substance which is a predecessor of a carnitine. Drug, oppressing activity of a γ-butyrobetainehydroxylase, reduces biosynthesis of a carnitine and transport of fatty acids with a long chain through membranes of cells, prevents accumulation in cells of the activated forms of unoxidized fatty acids – derivatives of an acylcarnitine And, thus preventing their negative action.

Vazopro recovers balance of processes of delivery of oxygen and its use in cells; prevents disturbance of transport of ATP, along with it activates glycolysis that is carried out without additional use of oxygen.

As a result of reduction of concentration of a carnitine the γ-butyrobetaine in which vasodilating properties are inherent is strenuously synthesized.

The mechanism of action of Vazopro defines a wide range of its pharmacological effects. It increases working capacity, reduces symptoms of a mental and physical overstrain.

Drug has the expressed cardiotyre-tread effect. At heart failure it improves sokratitelny ability of a myocardium, increases tolerance to exercise stresses. At stable stenocardia of II and III functional classes increases physical working ability of patients and reduces the frequency of attacks of stenocardia.

At acute and chronic ischemic disorders of cerebral circulation of Vazopro improves blood circulation in the ischemia center, influencing redistribution of cerebral circulation in favor of the ischemic site.

Tonic action on TsNS is inherent in Vazopro, it eliminates functional disturbances somatic and the autonomic nervous system, including at an abstinence syndrome at patients with an alcoholism. Drug has also positive impact on dystrophic the changed vessels of a retina and on cellular immunity.

Pharmacokinetics. After oral administration drug is quickly soaked up from digestive tract. Bioavailability makes 78%. The maximum concentration in a blood plasma is reached in 1-2 hours after reception. The elimination half-life makes 3-6 hours.
Pharmaceutical characteristics

Main physical and chemical properties:

capsules on 250 mg – solid gelatin capsules No. 1, the case of white color, a lid of pink color. Contents of capsules – crystal powder of white or almost white color with a slight smell. Powder hydroscopic;

capsules on 500 mg – solid gelatin capsules No. 00, the case of white color, a lid of pink color. Contents of capsules – crystal powder of white or almost white color with a slight smell. Powder hydroscopic.

Indications to use:

As a part of complex therapy of coronary heart disease (stenocardia, a myocardial infarction, chronic heart failure) and dishormonal cardiomyopathy; acute and chronic disorders of blood supply of a brain (brain strokes and chronic insufficiency of cerebral circulation); hemophthalmia and retinal apoplexies of a different etiology, fibrinferments of the central vein of a retina and its branches, retinopathies of various etiology (diabetic, hypertensive); reduced working capacity, physical overworks; an abstinence syndrome at an alcoholism (in a combination with specific therapy of alcoholism).

Route of administration and doses:

Drug is appointed the adult inside.

Cardiovascular diseases.

As a part of complex therapy – 500-1000 mg a day, at once all dose or having divided it into 2 receptions. A course of treatment – 4-6 weeks.

Cardialgia against the background of dishormonal dystrophy of a myocardium – on 500 mg a day. A course of treatment –  12 days.

Disturbances of cerebral circulation.

Acute phase – apply an injection form of drug within 10 days, further pass to oral administration 500-1000 mg a day, at one time or having divided a dose into       2 receptions. The general course of treatment – 4-6 weeks.

Chronic disturbances – inside on 500 mg a day. A course of treatment – 4-6 weeks. Repeated courses (usually 2-3 times a year) are possible after consultation of the doctor.

Vascular pathology and dystrophic diseases of a retina.

Apply an injection dosage form of drug.

Intellectual and physical overworks.

On 500 mg 2 times a day. A course of treatment – 10-14 days. If necessary treatment is repeated in 2-3 weeks.

Alcoholism.

On 500 mg 4 times a day. A course of treatment – 7-10 days.

Features of use:

Use during pregnancy or feeding by a breast

Safety of use of Vazopro during pregnancy is not proved therefore pregnant women should not appoint drug.

For Vazopro's treatment feeding by a breast should be stopped.
Children

Experience of use to children is absent.

Drug with care is used at chronic diseases of a liver and kidneys.

Because of possible development of the stimulating effect it is recommended to apply Vazopro in the first half of day.

Vazopro is not drug of the first row at an acute coronary syndrome.
Ability to influence speed of response at control of motor transport or work with other mechanisms

There are no data on a negative impact of Vazopro on speed of response.

Side effects:

From cardiovascular system: seldom – tachycardia, arrhythmia, changes of arterial pressure.

From system of a hemopoiesis: eosinophilia.

From the central nervous system: seldom – a headache, dizziness, psychomotor disturbances, paresthesias, a tremor, excitement.

From digestive tract: seldom – diarrhea, nausea, vomiting, an abdominal pain, the dispepsichesky phenomena, metal smack in a mouth, dryness in a mouth or hypersalivation.

Allergic reactions: seldom – reddening and an itch of skin, urticaria, rash, a Quincke's disease; very seldom – an acute anaphylaxis.

From respiratory system: short wind, dry cough.

Others: a fever, a stethalgia, weakness, a hyperthermia, the increased perspiration.

Interaction with other medicines:

Drug can be combined with anti-anginal means, anticoagulants and antiagregant, antiarrhytmic means, cardiac glycosides, diuretics, bronchial spasmolytics and other drugs.

Vazopro can exponentiate effect of nitroglycerine, nifedipine, β-adrenoblockers, anti-hypertensive means and peripheral vazodilatator.

Contraindications:

Hypersensitivity to drug components. The increased intracranial pressure (at disturbance of venous outflow, intracranial tumors). Organic lesions of the central nervous system (CNS).

Overdose:

There are no messages on cases of overdose of Vazopro. Drug малотоксичен.

The lowering of arterial pressure, headache, dizziness, tachycardia, the general weakness are possible. Symptomatic treatment.

In case of heavy overdose it is necessary to control function of a liver and kidneys.

Storage conditions:

Period of validity. 1 year 6 months. Not to use drug after the termination of the period of validity specified on packaging. To store in the dry place at a temperature not above 25 °C. To store in the place, unavailable to children.

Issue conditions:

According to the recipe

Packaging:

Capsules on 250 mg: on 10 capsules in the blister. On 4 blisters in a pack.

Capsules on 500 mg: on 10 capsules in the blister. On 6 blisters in a pack.